Benitec Biopharma is a clinical-stage biotechnology company developing DNA-directed RNA interference (ddRNAi) therapies that combine gene therapy delivery with durable gene silencing. Its platform aims for sustained knockdown of disease-causing genes after a single administration. Programs have included chronic conditions such as oculopharyngeal muscular dystrophy (OPMD); as a pre-commercial biotech it reports little to no product revenue.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -16.1 | — |
| Q3 2025 | 0 | — | -9 | — |
| Q4 2025 | 0 | — | -11.8 | — |
| Q1 2026 | 0 | — | -11.9 | — |
| Q2 2026 | 0 | — | -12.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Wilco 63 Corporation Class A Ordinary Shares (WLCO), Axiom Intelligence Acquisition Corp 1 (AXIN), Franklin Financial Services Corporation (FRAF), X3 Acquisition Corp. Ltd. (XCBE), The Hackett Group, Inc. (HCKT), 8x8, Inc. (EGHT)